News
NTHI
7.00
-37.83%
-4.26
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
NeOnc Technologies Partners with CBCC for Clinical Expansion
TipRanks · 1d ago
NeOnc Technologies receives RPDD for NEO100
TipRanks · 3d ago
Neonc Technologies Holdings Inc trading halted, volatility trading pause
TipRanks · 3d ago
Neonc Technologies Holdings Inc trading resumes
TipRanks · 3d ago
Weekly Report: what happened at NTHI last week (0324-0328)?
Weekly Report · 3d ago
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 3d ago
NEONC TECHNOLOGIES HOLDINGS, INC. RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FOR NEO100 IN TREATMENT OF PEDIATRIC-TYPE DIFFUSE HIGH-GRADE GLIOMAS
Reuters · 3d ago
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
U.S. IPO Weekly Recap: CoreWeave Fails To Impress In Downsized IPO, As More Names Join The Pipeline
Seeking Alpha · 5d ago
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
Barchart · 03/27 07:05
More
Webull provides a variety of real-time NTHI stock news. You can receive the latest news about NeOnc Technologies Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTHI
More
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).